Corcept Therapeutics
$114.03Change from previous close: −1.04%Absolute change: −$1.20
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $12.33B
- Enterprise value
- $12.03B
- P/E (trailing 12 months)
- 259.1
- Forward P/E
- 25.9
- PEG
- 0.81
- Price/book
- 17.4
- Price/sales
- 14.8
- EV/EBITDA
- 1,487.8
- EV/revenue
- 14.5
Profitability and growth
- Gross margin
- 98.3%
- Operating margin
- 16.1%
- Net margin
- 6.6%
- ROE
- 8.2%
- ROA
- 0.5%
- Revenue growth (year over year)
- 31.7%
- Earnings growth (year over year)
- 24.1%
Financial health
- Total cash
- $308.2M
- Total debt
- $9.42M
- Debt/equity
- 0.01
- Current ratio
- 2.86
- Quick ratio
- 2.50
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $141.00
- Median price target
- $164.00
- High price target
- $165.00
- Low price target
- $50.00
- Analysts with a price target
- 5
- Consensus
- Buy
- Forward EPS
- $4.40
- EPS estimate, current year
- $2.15
Shares and trading
- Beta
- 0.45
- Average volume
- 1.33M
- Shares outstanding
- 108.1M
- Float
- 96.48M
- Institutional ownership
- 76.7%
- Insider ownership
- 11.5%
- Short interest (% of float)
- 11.1%
- Short ratio (days)
- 10.7